[go: up one dir, main page]

MX2014011583A - Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. - Google Patents

Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.

Info

Publication number
MX2014011583A
MX2014011583A MX2014011583A MX2014011583A MX2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A
Authority
MX
Mexico
Prior art keywords
family
compositions
treatment
methods
tomors
Prior art date
Application number
MX2014011583A
Other languages
English (en)
Other versions
MX377618B (es
Inventor
Jeffrey A Toretsky
Milton Lang Brown
Perrer N Tosso
Aykut Uren
Yali Kong
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of MX2014011583A publication Critical patent/MX2014011583A/es
Publication of MX377618B publication Critical patent/MX377618B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporcionan compuestos, composiciones y métodos que se relacionan a inhibidores de la proteína EWS-FLI1. Los compuestos tiene utilidad en el tratamiento de cánceres incluyendo la familia de tumores del Sarcoma de Ewing.
MX2014011583A 2012-04-12 2013-04-11 Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. MX377618B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623349P 2012-04-12 2012-04-12
PCT/US2013/036234 WO2013155341A1 (en) 2012-04-12 2013-04-11 Methods and compositions for treating ewings sarcoma family of tumors

Publications (2)

Publication Number Publication Date
MX2014011583A true MX2014011583A (es) 2016-02-09
MX377618B MX377618B (es) 2025-03-07

Family

ID=49328171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011583A MX377618B (es) 2012-04-12 2013-04-11 Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.

Country Status (12)

Country Link
US (2) US9290449B2 (es)
EP (1) EP2836481B1 (es)
JP (2) JP6130491B2 (es)
KR (1) KR102145835B1 (es)
CN (2) CN104395288B (es)
AU (2) AU2013245812B2 (es)
CA (1) CA2869513C (es)
IL (1) IL234993B (es)
IN (1) IN2014DN09228A (es)
MX (1) MX377618B (es)
NZ (2) NZ700612A (es)
WO (1) WO2013155341A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443750B2 (ja) 1994-06-24 2003-09-08 キョーラク株式会社 ダボ付きパネル
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
CA2869513C (en) * 2012-04-12 2020-07-07 Georgetown University Methods and compositions for treating ewings sarcoma family of tumors
CA2927148A1 (en) 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
CN107108580B (zh) * 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
DK3436434T3 (da) 2016-03-31 2020-09-21 Oncternal Therapeutics Inc Indolin-analoger og anvendelser deraf
MX395539B (es) 2016-07-29 2025-03-25 Oncternal Therapeutics Inc Usos de compuestos de indolinona
WO2018119069A1 (en) * 2016-12-21 2018-06-28 Mooberry Susan L Altertoxin ii as a selective inhibitor of ewing family of tumor cells
CN108186630B (zh) * 2017-12-18 2020-07-31 温州医科大学 靛红类似物在制备抗肿瘤药物中的应用
CN110870917B (zh) * 2018-09-03 2022-03-15 上海市第一人民医院 Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用
US12076310B2 (en) * 2021-06-09 2024-09-03 University Of Rochester Compounds and methods for the treatment of acute myelogenous leukemia
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
WO2023178040A2 (en) * 2022-03-13 2023-09-21 University Of Virginia Patent Foundation Inhibitors of ews-fli1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
DE69922997T2 (de) 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
EP2124910A4 (en) 2006-12-29 2012-02-15 Univ Georgetown ANTITUMOR THERAPY BY TARGETING EWS-FLI1
MX2009011281A (es) * 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US8377992B2 (en) * 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CA2869513C (en) 2012-04-12 2020-07-07 Georgetown University Methods and compositions for treating ewings sarcoma family of tumors
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
CA2927148A1 (en) 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
CN107108580B (zh) 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途

Also Published As

Publication number Publication date
NZ700612A (en) 2016-09-30
AU2013245812B2 (en) 2017-04-06
KR20150007311A (ko) 2015-01-20
EP2836481A4 (en) 2015-11-18
AU2013245812A2 (en) 2014-11-20
US9290449B2 (en) 2016-03-22
EP2836481B1 (en) 2018-12-26
AU2013245812A1 (en) 2014-11-13
AU2017201507A1 (en) 2017-03-23
JP6130491B2 (ja) 2017-05-17
CN107011242B (zh) 2020-08-07
IL234993B (en) 2019-02-28
CN104395288A (zh) 2015-03-04
JP2015512943A (ja) 2015-04-30
JP6345301B2 (ja) 2018-06-20
MX377618B (es) 2025-03-07
HK1207368A1 (en) 2016-01-29
CA2869513C (en) 2020-07-07
NZ723971A (en) 2018-01-26
CN104395288B (zh) 2016-12-14
IN2014DN09228A (es) 2015-07-10
US9714222B2 (en) 2017-07-25
JP2017141290A (ja) 2017-08-17
EP2836481A1 (en) 2015-02-18
CA2869513A1 (en) 2013-10-17
US20160159741A1 (en) 2016-06-09
CN107011242A (zh) 2017-08-04
WO2013155341A1 (en) 2013-10-17
AU2017201507B2 (en) 2018-10-04
KR102145835B1 (ko) 2020-08-20
US20150051260A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
NI201900019A (es) Inhibidores de procesos metabólicos celulares
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
CR20150316A (es) Compuestos y sus métodos de empleo
EA201400178A1 (ru) Лечение рака молочной железы
AR091837A1 (es) Compuestos para inmunoterapia dirigida
UY34763A (es) Inhibidores de la agregación plaquetaria
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2016007972A (es) Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
MX378288B (es) Inhibidores de pirimidina del fgfr4.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CR20150483A (es) Composiciones y métodos para el diagnóstico y tratamiento del cáncer hepático
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
MX2019010875A (es) Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201491610A1 (ru) Модуляторы x рецепторов печени
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
UA116654C2 (uk) Похідні пурину як агоністи канабіноїдного рецептора св2
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer

Legal Events

Date Code Title Description
FG Grant or registration